{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:53:45Z","timestamp":1778781225929,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that frequently affects the kidneys and lungs. Avacopan, a C5a receptor inhibitor, has demonstrated efficacy as a glucocorticoid-sparing therapy, but data on rare or severe manifestations, such as interstitial lung disease (ILD), cardiac involvement, and epididymo-orchitis, remain limited. We report two patients with newly diagnosed AAV and severe kidney involvement requiring hemodialysis. Case 1, a 65-year-old man with MPO-AAV, presented with ILD with a Usual Interstitial Pneumonia (UIP) radiological pattern, cardiac dysfunction, ENT involvement, and peripheral neuropathy. Case 2, a 68-year-old man with PR3-AAV, presented with kidney disease and epididymo-orchitis. Both patients received corticosteroids, rituximab, cyclophosphamide, plasma exchange, and avacopan. Dialysis independence was achieved within the first month in both cases. In Case 1, left ventricular function normalized, and ILD showed radiological improvement over 6 months. In Case 2, epididymo-orchitis resolved completely within 1 month. Both patients achieved clinical remission with minimal glucocorticoid exposure. These cases provide insights supporting the safety and efficacy of avacopan in severe, multisystemic AAV, including rare manifestations, and highlight its potential to promote organ recovery and reduce glucocorticoid-related toxicity in high-risk presentations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1717889","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:40Z","timestamp":1765175380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Challenging manifestations of ANCA-associated vasculitis treated with avacopan: two case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Aglaia","family":"Chalkia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Politi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isavella","family":"Tryfonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harikleia","family":"Gakiopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Petras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102495","article-title":"Clinical associations of renal involvement in ANCA-associated vasculitis","volume":"19","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis\u2014treatment standard","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e11795","DOI":"10.1002\/acr2.11795","article-title":"Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Specks","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.05.041","article-title":"Treatment with avacopan in ANCA-associated vasculitis with kidney involvement","volume":"10","author":"Geetha","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000274","article-title":"The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials","volume":"35","author":"Bate","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae020","article-title":"Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161224","article-title":"Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: The influence of ANCA subtype","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000979","article-title":"Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment","volume":"29","author":"Turgeon","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.08.024","article-title":"Interstitial pneumonia associated with MPO-ANCA: Clinicopathological features of nine patients","volume":"106","author":"Tanaka","year":"2012","journal-title":"Respir Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1479973121994562","article-title":"Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis","volume":"18","author":"Zhou","year":"2021","journal-title":"Chron Respir Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"S\u00e1nchez \u00c1lamo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e11795","DOI":"10.1002\/acr2.11795","article-title":"Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"7","author":"Specks","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15408","article-title":"Role of intracellular complement activation in kidney fibrosis","volume":"178","author":"Portilla","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf070","article-title":"Cardiovascular involvement in ANCA-associated vasculitis","volume":"40","author":"Sarmad","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:40Z","timestamp":1765175380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1717889"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1717889","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1717889"}}